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Abstract
Chagas disease (ChD) is caused by Trypanosoma cruzi (T. cruzi), an intracellular
protozoan parasite. ChD has a global mortality of 15,000 annual deaths, and approximately, 8-10
million people are infected. There is growing concern in the United States as autochthonous cases
of ChD have been reported in the southern region. The two available treatments are only partially
effective and highly toxic. N-aroyl derivatives and α, β-unsaturated ketones have been previously
tested against Leishmania, a closely related parasite, demonstrating selective toxicity towards the
microorganism. The objective of this study is to evaluate a drug library consisting of 21 α, βunsaturated ketones and 15 N-aroyl derivatives as anti-trypanosomal treatments. We hypothesized
there will be at least one effective candidate from the drug libraries against T. cruzi. Highthroughput screening was used to evaluate this. Epimastigote forms of T. cruzi CL Brenner-luc
were used to assess the anti-parasitic activity of the compounds through a luciferase viability assay.
Six compounds showed low toxicity to Human bone osteosarcoma epithelial cells (U2OS) and
Rhesus monkey kidney epithelial cells (LLC-MK2). Six of α, β-unsaturated ketones and three Naroyl compounds showed good anti-trypanosomal activity with an EC50 ranging from 0.19 nM to
1.00 μM and a selectivity index (SI) ranging from 33 to 526. Our future directions include a) to
determine the compounds activity against amastigotes (intracellular form of the parasite) by HighContent Imaging (HCI), b) tested in the murine model of Chagas disease and c) to explore the
possible mode of action of the lead(s) compounds.
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Chapter 1: General Information
1.1 Chagas Disease Importance
Chagas disease (ChD) is caused by the infection of the protozoan parasite Trypanosoma
cruzi. It is an endemic disease in Latin America [1]. The prevalence of this disease is more notable
in rural communities. It is estimated that 6 to 7 million people are infected worldwide [2].
Currently, more than 300,000 patients in the United States are evaluated to be chronically infected
with Chagas Disease [4-5]. Most of the focus of infection in the U.S. is in southern states as shown
in Figure 1. The main route of transmission is by triatomine (known as “kissing bug” in the United
States) vector, as well as blood transfusion, organ transplants, and contaminated food or beverages.
[4, 11]. In recent decades patients have been found positive in the United States and Europe due
to globalization and the prominence of these vectors in those areas. T. cruzi infection in Texas
(Figure 1 and 2) [11].
Chagas disease infection consists of two phases, the acute phase and the chronic phase [5].
The acute phase consisting from the time of the infection up to weeks or months. A few patients
develop symptoms at the acute phase such as, “chagoma” (inflammation at the infection area),
fever, nausea, between other general symptoms [5-7]. Early detection at the acute phase can
influence the faith of the patient. Patient’s early treatment can help predict a satisfactory outcome.
At the end of the acute phase, symptomatic patients stop showing any symptoms. Consequently,
infection switches into the chronic phase [10]. The chronic phase lasting life-long without
treatment [5]. Approximately 20-30% of patients suffering with chronic stage will develop
abnormal organ outgrowth causing heart failure (cardiomyopathy) and/or gastrointestinal
problems (megacolon and/or megaesophagus) [6, 16].
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1.2 Trypanosoma cruzi Life Cycle
The replicative stage (non-infective), known as epimastigotes T. cruzi are found in the midgut
of the triatomine [11]. Thereafter, the parasite is transported to the hindgut where it transforms to
the infective form, metacyclic trypomastigotes T. cruzi. When the triatomine takes a blood meal
from the host, it deposits infected feces containing metacyclic trypomastigotes, simultaneously.
Metacyclic trypomastigotes parasites can be introduced to any mucosal membrane (eye, nose or
mouth) or through a bite wound if the feces are deposited close enough. In such event, parasites
can invade the host cells. Within the cell, the metacyclic trypomastigote will transform into
intracellular amastigotes. The intracellular amastigotes will reproduce by binary fission and
convert into intracellular trypomastigotes causing the cell to burst. Subsequently, the
trypomastigotes will infect adjacent cells and/or ingested through a blood meal uptake of another
triatomine. When the parasite infects the triatomine, it will be converted into epimastigote T. cruzi
in the midgut. After the epimastigotes migrate to the hindgut undergoing metacyclogenesis
transforming metacyclic trypomastigote, repeating its life cycle (Figure 3) [10].

1.3 Current Treatments
Nifurtimox and benznidazole are the only market drugs available and both have FDA approval.
The compounds can be used together or separate, depending on the response of the patient. They
are most effective when the patient is on the acute phase [16, 17, 18]. However, there is only an
approximate 15% of effectivity when the patient is on the chronic stage [17]. On the other hand,
treatment using these compounds is long lasting up to 60 days and are highly toxic. Therefore, we
are in a search for a novel treatment against T. cruzi infection in the chronic phase [8, 10, 18].
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Figure 1. Estimation of Chagas Disease Cases in the United States, 2012. [6].
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Figure 2. Demographic distribution of Trypanosoma cruzi infection in Texas (2013-2018)
[7].
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Figure 3. Life cycle of Trypanosoma cruzi.
https://www.cdc.gov/parasites/images/chagas/AmerTryp_LifeCycle.gif
Figure 3. Life cycle of Trypanosoma cruzi
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Chapter 2: Therapeautic Effect Analysis of α, β-unsaturated ketones and
N-aroyl derivatives
2.1 α, β-unsaturated Ketones and N-aroyl Derivatives
Previous studies performed by our laboratory have shown that the organic compounds, α,
β-unsaturated ketones and N-aroyl derivatives, have a potential anti-trypanosomal activity to be a
potential treatment for Chagas disease [9]. Trypanosomatids carry a thiol-dependent metabolism
which is used as a detoxification defense mechanism [16]. The organic compounds, α, βunsaturated ketones (enols) and N-aroyl derivatives drugs have shown potential interaction with
cellular thiols [14]. The unsaturated ketone alkylate, the N-acetyl-L-cysteine and other
biomolecules that contain a thiol group and the phenolic hydroxy group behave as a free oxygen
radical scavenger [15, 22]. These types of compounds have previously been published in our lab
against the protozoan parasite Leishmania major [23, 24]. Trypanosoma cruzi and Leishmania
major belong to the Trypanosomatidae family [9]. Both species contain a thiol-dependent
detoxification defense mechanism using a redox pathway [12, 16, 21]. This relatedness indicate
that the activity of the compounds will have good anti-parasitic effects.

2.2 Hypothesis
We hypothesize that the new generation of α, β-unsaturated ketones and N-aroyl
derivatives will have improved antiparasitic activity against Trypanosoma cruzi.

SPECIFIC AIM 1 – To determine the potential toxicity of α, β-unsaturated ketones and
N-aroyl derivatives against mammal cells using an in vitro toxicity assay. The cell lines used will
be Human Bone Osteosarcoma Epithelial Cells (U2OS) and Rhesus monkey kidney epithelial cells
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(LLC-MK2) at different concentrations of the α, β-unsaturated ketones and N-aroyl derivatives
compounds.

SPECIFIC AIM 2 – To evaluate the anti-trypanosomal activity of the α, β-unsaturated
ketones and N-aroyl derivatives. The drug screening will be accomplished by a bioluminescent
assay using T. cruzi CL Brenner-luc, which overexpresses luciferase. Several concentrations of the
new generation of α, β-unsaturated ketones and N-aroyl derivatives will be used to treat the
parasites.

2.3 Materials and Methods

2.3.1 Cellular Strains and Compounds Tested
The parasite strain used was Trypanosoma cruzi CL Brener-luc, a transgenic mutant
overexpressing luciferase, the Human Bone Osteosarcoma Epithelial Cells (U2OS) and Rhesus
monkey kidney epithelial cells (LLC-MK2).
Two sets of compounds were tested, 21 α, β-unsaturated ketones and 15 N-aroyl derivatives.
Compounds were provided by our collaborator Dr. Jonathan Dimmock from The University of
Saskatchewan, Canada.
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Table 1. The compound structures were drawn using the “Draw structure” tool available at
ChemSpider by the Royal Society of Chemistry

α, β-unsaturated ketones
1833

2446

2443

2553

2453

2548

1834

2423

8

2550

2551

2552

2444

2549

2554

2062

2555

9

2556

2557

2558

2448

1831

10

N-aroyl derivatives
2567

2067

2572

2559

2560

2561

2562

2563

11

2564

2565

2566

2568

2569

2570

12

2571

13

2.3.2 Epimastigote T. cruzi Culture
Epimastigote T. cruzi CL Brenner-luc was cultured in LIT (Liver Infusion Tryptose, 10%
inactivated FBS) media with G418 antibiotic [8].

2.3.3 Mammalian Cell Culture
Human bone osteosarcoma epithelial cells U2OS (ATCC # HTB-96) and Rhesus monkey
kidney epithelial cells LLC-MK2 (ATCC # CCL-7) were cultured in DMEM (Dulbecco's
Modified Eagle Medium) with 10% iFBS (heat-inactivated Fetal Bovine Serum) and 1%
antibiotics ampicillin (10,000 U/mL) and streptomycin (10,000 μ/mL) in 0.9% sodium chloride.

2.3.4 In vitro Epimastigote Trypanosoma cruzi Luciferase Assay
The survival of the parasite T. cruzi CL Brenner-luc was obtained by the direct measure
of bioluminescence. This procedure was performed three independent times in quadruplicates.
T. cruzi culture was transferred into a 50 mL conical tube and centrifuged at 3000 rpm for
5 min. The supernatant was discarded and the pellet was kept. The pellet was resuspended on 1
mL of LIT supplemented with 200 M G418. The suspension was transferred to a 1 mL
microcentrifuge tube. The parasites were counted using a hematocytometer to obtain a final
concentration of 1x106 parasite per well.
The parasites were added in a 96-well transparent plate with transparent flat bottom with
the exception of the blank control (media only), followed by the addition of the compounds diluted
in media. In a concentration range from 1.00 μM to 8 nM (stock dilution in DMSO). The plate was
incubated at 37 C
ͦ for 72 hrs. After incubation, 35 L of Dual-Glo® Luciferase Assay System was
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added. The plates were analyzed using the Thermo Luminoskan Ascent Microplate Reader and the
data obtained was normalized. Data normalization was adjusted using each plate’s controls.

2.3.5 In vitro U2OS and LLC-MK2 Mammalian Cell Line Toxicity
The media was removed from the culture flask and the cells washed twice with 5 mL of
warm PBS (phosphate-buffered saline) into the flask. Thereafter, trypsin was added and incubated
at 37 ͦC for 5 min. After incubation, 8 mL of DMEM supplemented with 10% inactivated FBS
(Fetal Bovine Serum) and 5 mL of penicillin and streptomycin. The suspension is then transferred
to a 50 mL conical tube, kept on ice, to then be counted using a hematocytometer.
The cells were added to the 96-well Falcon black/ clear bottom plate to incubate 37 C
ͦ for
4 hrs. for cells seeding. The controls used were 1% DMSO (positive) and Benznidazole at a final
concentration of 800 μM (negative). After incubation the drugs were added in concentration range
from 66 μM to 8.25 μM (U2OS) and 100.0 μM to 1.5 μM (LLC-MK2). Follow, the plate was
incubated at 37 C
ͦ 5% CO2 for 72 hrs. After incubation, 2% of Hoechst and 2% of PI (propidium
iodine) was added to each well for staining and incubated for 1 hr. at 37 C
ͦ . The plate was analyzed
using the In-Cell Analyzer.

15

Figure 4. Epimastigote T. cruzi Cl Brenner-luc and U2OS cell line toxicity flow chart.
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2.4 Results.

2.4.1 Cytotoxicity Analysis of N-aroyl Derivatives and α, β-unsaturated Ketones
Treatments Against T. cruzi CL Brenner-luc in vitro
The agents were pre-screened to observe their anti-parasitic effectivity against
epimastigote T. cruzi CL Brenner-luc in vitro. The highest concentration tested was 1.00 μM,
followed by 0.50 μM and 0.25 μM. The parasites were treated with the compounds and incubated
for 72 hrs. at 37 C
ͦ .
Many compounds were discarded at the first trial since they showed partial to nonantiparasitic effects. In figure 5, six compound that showed antiparasitic effects are shown. The
compounds NC2443, NC2067, NC2507, NC1833, NC2553, and NC2446 showed an EC50 below
the concentration of 0.50 μM. The compounds NC2067 and NC1833 reached the EC50 at the
around 18 μM, NC2446 and NC2567 at 0.50 μM and NC2443 and NC2553 did not reach their
EC50. The calculated z-score was 0.8689 with a p-value of 0.0440 with alpha 0.05 portraying
significance among treatments.
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T. cruzi CL Brenner-luc Cytotoxicity 72 hrs
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Figure 5. Cytotoxicity assay for α, β-unsaturated ketones treating T. cruzi. Assay yield significant
effect (P-value = 0.0440 α=0.05)
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2.4.2 Toxicity Analysis Against U2OS and LLC-MK2 Mammalian Cell Lines Using N-aroyl
Derivatives and α, β-unsaturated Ketones Treatment in vitro
The compounds that showed anti-trypanosomal activity were further tested against U2OS
(human bone osteosarcoma epithelial cells) and LLC-MK2 (Rhesus monkey kidney epithelial
cells) cell lines, independently. A concentration of 104 cells were added to each well. After cell
seeding, the treatment was added and incubated for 72 hrs. After incubation, the cells were
analyzed using a live/dead assay with staining using Hoechst and PI dyes. The procedure allowed
us to differentiate and determine the live cells percentage.
The compounds NC2553 and NC1833 showed low toxicity against U2OS cell line with
survival of 80% at the highest concentration of 66 μM. Compounds NC2443, NC2446, NC2067
and NC2567 showed an approximate EC50 of 45 μM. The controls used were untreated acting as
our positive control, 1% DMSO as our vehicle control and 1% hydrogen peroxide as our negative
control. Our choice of 1% peroxide was used to obtain cell death baseline. Compounds that showed
low toxicity are strong candidates for in vivo trials. The calculated z-score was 0.9096, this is a
reflection of an accurate assay as it is less than one standard deviation from the mean.
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U2OS Toxicity 72 hrs
100
90

Untreated
DMSO 1%

Survival (%)

80

Hydrogen Peroxide

70

1833
2553

60

2443
2446

50

2067
2567

40
30
20
10
0

8.25

16.5

66

C

Concentration (M)
Figure 6. Cytotoxicity Assay Against U2OS Cell Line at three different concentrations of α, βunsaturated ketones. The highest concentration of the compound was 66 μM, diluted two times.
Assay yield a highly significant effect (P-value<0.0001, α=0.05)
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The compound NC1833 showed the lowest toxicity against LLC-MK2 cells with a survival over
50% at its highest concentration of 100 μM, followed by NC 2446 with an EC50 of 75 μM. The
compounds NC2553, NC2443, NC2067, and NC2567 had an EC50 ranging from 12-37 μM shown
in Table 1. The positive control was untreated cells, followed by 1% DMSO as the vehicle control.
800 μM Benznidazole was used instead of 1% hydrogen peroxide; we wanted to compare our
compound toxicity against mammalian cells to the current approved treatment. The survival shown
for 800 μM Benznidazole was lower than 50%. The calculated z-score was 0.7736, measurement
of accuracy of this assay.
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LLC-MK2 Toxicity 72 hrs

Survival (%)

100
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Figure 7. Cytotoxicity Assay Against LLC-MK2 Cell Line at seven different concentrations of α,
β-unsaturated ketones. The highest concentration of the compound was 100 μM, serial diluted
six times. Assay yield highly significant values of treatments (P-value<0.0001, α=0.05)
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2.4.3 Calculation of Selective Index (SI)
The selective index was calculated by dividing the EC50 of the compound against T. cruzi
over the EC50 of compound causing toxicity against the mammalian cell lines. The SI allowed us
to the window range of toxicity of the compounds against epimastigote T. cruzi CL Brenner-luc
and U2OS human cell line in vitro. The selective index (SI) was calculated by dividing the EC50
of the compound against T. cruzi over the EC50 of compound causing toxicity against the
mammalian cell line.
The compound with the highest selective index is NC1833 towards U2OS at 347 and LLCMK2 at 526. This compound offered the highest selectivity against T. cruzi while showing low
toxicity against both mammalian cells. The compound that followed was NC2567 with an SI of
237 with U2OS cell line and 195 with LLC-MK2. The third most selective compound was NC2446
with an SI with U2OS of 90 and 200 for LLC-MK2. While the compounds NC2553, NC2443 and
NC2067 showed an SI range from 33-72.
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Table 2. Calculated EC50 table of cytotoxicity assay against epimastigote T. cruzi and toxicity
assays against U2OS and LLC-MK2 cell lines, independently
Drug

Epimastigotes (µM)

U2OS (µM)

Selective
Index

LLC-LMK2 (µM)

Selective
Index

2553

1

66

66

37

37

2443

1

42

66

37

37

2446

0.5

45

90

100

200

2067

0.25

8.25

33

18

72

2567

0.19

45

237

37

195

1833

0.19

66

347

100

526
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Table 3. Two-way ANOVA analysis of drug concentration and toxicity among treatments. The
quality of the assays was calculated by z-score and two-way ANOVA, α=0.05. Z-score test and
ANOVA were performed based on GraphPad article “Calculating a Z-factor to assess the quality
of a screening assay” and GraphPad group comparison analysis. This helped us determine the
accuracy and significance of the experiments.
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2.5 Conclusion and Future Directions
The discovery of a novel treatment for Chagas disease is necessary since millions of
patients in indigenous areas in Central and South America suffer from this morbid disease.
Migration of the illness in recent years will also affect more communities around the globe,
including the United States. An estimate of 8 million people is presumed to be infected making
the development of a treatment of utmost importance. The treatments available are not easily
accessible to low socioeconomic populations in rural areas. Additionally, the current treatments
are highly toxic and poorly effective in the chronic stage. Previous research of these compounds
against closely related parasite, Leishmania major, were proven effective on in vitro models. Thus,
these novel compounds provide promising anti-parasitic effects against T. cruzi with low toxic
effects against mammalian cells in vitro.
This research indicates that N-aroyl derivatives and α, β-unsaturated ketones drugs are
potential drug candidates against T. cruzi. The z-scores of all three assays were between 0.5 and
1.0, according to the GraphPad article these values classify our assay as excellent. Two-way
ANOVA was performed with independent variables of drug concentration and survival. It showed
a significance level of p<0.0001 for LMK-2 and U2OS cell lines and p=0.0440 for T. cruzi, which
proves significant within our confidence interval of α=0.05. Therefore, we fail to reject our
hypothesis and treatments can move to next stage of experimentation.
The SI of 6 the total compounds, ranged from 33 to 526. Our leading compound NC1833
showed high anti-parasitic effects against T. cruzi CL Brenner-luc at the concentration of 19 nM
and 80% cell survival against U2OS mammalian cell line at the concentration of 66 μM, (SI of
347) and more than 50% survival against LLC-MK2 cell line (SI of 526). High selective indexes
are indicative of a larger therapeutic window when tested in a murine model. The results obtained
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create a baseline of the effectivity against trypomastigotes and the existing toxicity to mammal
cells. Experiments were performed in triplicates and were proven to be replicable as they were
repeated at least three different times with similar results. Error bars are shown in all graphs to
portray this.
Future directions for this project are testing its anti-proliferative effects to further
discriminate compounds and select the most effective ones. Proliferation assay will be performed
as follows: Cell lines U2OS and LLC-MK2, will be infected with trypomastigote T. cruzi CL
Brenner-luc. After infection the cells will be treated with our leading compounds independently.
The cells will then be incubated at 37 C
ͦ for 48 hrs. After incubation, the cells will be fixed using
4% paraformaldehyde. Once fixed, they will be stained using the Alexa Flour 488 green and DAPI.
Image acquisition and analysis will be performed using Biotek’s Cytation 5 Cell Imaging MultiMode Reader.
The in vitro cytotoxicity and the proliferation assays will allow us to determine if these
compounds are good candidates to be tested in a murine model. It is necessary to understand if
these novel treatments can stop the intracellular amastigotes proliferation within the cell. These
promising results fulfill our specific aims and indicate that N-aroyl derivatives and α, β-unsaturated
ketones drugs are potential candidates for treatment against T. cruzi as we fail to reject our
hypothesis.
This array of compounds has shown the potential to become novel treatments against
Chagas Disease. This is highly important due to the lack of treatments available. The compounds
have shown to have lower toxicity levels against mammalian cells and good antiparasitic effects
compared to the Benznidazole. This project creates a background for future research using N-aroyl
derivatives and α, β-unsaturated ketones to treat Chagas Disease.
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Figure 8. Intracellular amastigote T. cruzi CL Brenner-luc proliferation assay flow chart
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